The price of the drug would be comparable to some other drugs that treat rare diseases. A spokeswoman for Biogen said the company set the price after considering several factors, including the cost to the health care system and the clinical value it brought to patients. She said that the company has also consulted insurers about covering the drug, and that while the talks are in their early stages, insurers have responded positively to the drugâ€™s effectiveness. " 